lead-radioisotopes and Prostatic-Neoplasms--Castration-Resistant

To summarise data with radium-223 dichloride (. Literature for this systematic review was identified using a PubMed search: ("targeted alpha therapy" or "targeted alpha particle therapy") or (213-bismuth or bismuth-213 or 213Bi) or (225-actinium or actinium-225 or 225Ac) or (211-astatine or astatine-211 or 211At) or (212-lead or lead-212 or 212Pb) or (227-thorium or thorium-227 or 227Th) or (223-radium or radium-223 or 223Ra or alpharadin) and (malignancy or cancer). Results were limited to English-language publications in humans, with the article type "clinical trial".. Forty-one publications were included (30 from the literature search and 11 from manual searches/reviews). In clinical trials in mCRPC,

Topics: Actinium; Astatine; Bismuth; Bone Neoplasms; Humans; Lead Radioisotopes; Male; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Thorium

We recently identified CD46 as a novel prostate cancer cell surface antigen that shows lineage independent expression in both adenocarcinoma and small cell neuroendocrine subtypes of metastatic castration resistant prostate cancer (mCRPC), discovered an internalizing human monoclonal antibody YS5 that binds to a tumor selective CD46 epitope, and developed a microtubule inhibitor-based antibody drug conjugate that is in a multi-center phase I trial for mCRPC (NCT03575819). Here we report the development of a novel CD46-targeted alpha therapy based on YS5. We conjugated

Topics: Alpha Particles; Animals; Humans; Lead; Lead Radioisotopes; Male; Membrane Cofactor Protein; Prostatic Neoplasms, Castration-Resistant; Radioimmunotherapy